NCT04575116已完成1 期
A PHASE 1, OPEN-LABEL, RANDOMIZED, CROSSOVER, SINGLE DOSE STUDY TO DETERMINE THE BIOEQUIVALENCE OF 12.2 MG TAFAMIDIS FREE ACID TABLET AND COMMERCIAL 20 MG TAFAMIDIS MEGLUMINE CAPSULE ADMINISTERED UNDER FASTED CONDITIONS TO HEALTHY PARTICIPANTS
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 23
- 试验地点
- 1
- 主要终点
- Area under the concentration-time curve (AUCinf)
研究概览
简要总结
Study to characterize the bioequivalence of a 12.2 mg free acid tablets compared to commercial supply (tafamidis meglumine soft gelatin 20 mg capsule) in healthy participants under fasted conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female participants must be 18 to 55 years of age, inclusive, at the time of signing the ICD.
- •Healthy female participants of nonchildbearing potential and/or male participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiovascular tests.
- •Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.
- •BMI of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
- •Capable of giving signed informed consent and compliance with study requirements and restrictions
排除标准
- •Medical Conditions:
- •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
- •Any condition possibly affecting drug absorption (eg, gastrectomy).
- •History of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, HBsAg, HBcAb, or HCVAb. Hepatitis B vaccination is allowed.
- •Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- •Prior/Concomitant Therapy:
- •Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention.
- •Prior/Concurrent Clinical Study Experience:
- •Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).
- •Diagnostic Assessments:
- •A positive urine drug test.
- •Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest. If BP is ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility.
- •Baseline 12 lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, baseline QTc interval >450 msec, complete LBBB, signs of an acute or indeterminate age myocardial infarction, ST T interval changes suggestive of myocardial ischemia, second or third degree AV block, or serious bradyarrhythmias or tachyarrhythmias). If the baseline uncorrected QT interval is >450 msec, this interval should be rate corrected using the Fridericia method and the resulting QTcF should be used for decision making and reporting. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTc or QRS values should be used to determine the participant's eligibility. Computer interpreted ECGs should be overread by a physician experienced in reading ECGs before excluding participants.
- •Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:
- •AST or ALT level greater than or equal to 1.5 × upper limit of normal (ULN);
- •Total bilirubin level greater than or equal 1.5 × ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is greater than or equal ULN.
- •Other Exclusions:
- •History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening. Binge drinking is defined as a pattern of 5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, alcohol intake should not exceed 14 units per week (1 unit = 8 ounces (240 mL) beer, 1 ounce (30 mL) of 40% spirit or 3 ounces (90 mL) of wine).
- •Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
- •History of sensitivity to heparin or heparin induced thrombocytopenia.
- •Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of this protocol.
- •Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
- •Use of tobacco or nicotine-containing products in excess of the equivalent of 5 cigarettes per day.
研究组 & 干预措施
Tafamidis Free acid tablet then tafamidis meglumine capsule
Experimental
On Day 1 of each period, participants will receive a single dose of 1 of tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug.
干预措施: Tafamidis free acid tablet (Drug)
Tafamidis Free acid tablet then tafamidis meglumine capsule
Experimental
On Day 1 of each period, participants will receive a single dose of 1 of tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug.
干预措施: Tafamidis meglumine capsule (Drug)
Tafamidis meglumine capsule then Tafamidis Free acid tablet
Experimental
On Day 1 of each period, participants will receive a single dose of 1 of tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug.
干预措施: Tafamidis free acid tablet (Drug)
Tafamidis meglumine capsule then Tafamidis Free acid tablet
Experimental
On Day 1 of each period, participants will receive a single dose of 1 of tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug.
干预措施: Tafamidis meglumine capsule (Drug)
结局指标
主要结局
Area under the concentration-time curve (AUCinf)
时间窗: Hour 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168
Area under the plasma concentration time profile from time zero extrapolated to infinite time
Maximum observed plasma concentration (Cmax)
时间窗: Hour 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168
Peak or maximum observed concentration
次要结局
- Area under the plasma concentration-time curve (AUClast)(Hour 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168)
- Number of patients with change in ECG parameters(Baseline up to Day 25)
- Area under the plasma concentration-time curve (AUC72)(Hour 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72)
- Time to Reach Maximum Observed Plasma Concentration (Tmax)(Hour 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168)
- Mean residence time (MRT)(Hour 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168)
- Plasma Decay Half-Life (t1/2)(Hour 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168)
- Number or percentage of patients with abnormal physical examination findings(Baseline up to Day 25)
- Number or percentage of patients with change from baseline in Clinical Laboratory parameters(Baseline up to Day 25)
- Number or percentage of patients with change from baseline in Vital sign measurements(Baseline up to Day 25)
- Incidence of adverse events(Baseline up to Day 46)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Bioequivalence And Food Effect Study Of Bosutinib In Healthy SubjectsPhiladelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML)NCT01374139Pfizer88
已完成
1 期
A Phase 1 Bioequivalence Study of a Test Tablet Formulation of Ravidasvir With the Reference Tablet Formulation of Ravidasvir StudyBioequivalence StudyNCT03602300Drugs for Neglected Diseases37
已完成
1 期
Phase1, Single Dose, Crossover Study to Determine BioequivalenceHealthyNCT00786240Pfizer37
已完成
1 期
A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy ParticipantsNeoplasm, Advanced or MetastaticNCT02625259Millennium Pharmaceuticals, Inc.54
已完成
1 期
Bioequivalence of TF3 and TF2 and Effect of Food on the PK of TepotinibHealthyNCT03629223Merck KGaA, Darmstadt, Germany66